BRCA1 and breast carcinoma: Incorporating additional data, such as biomarkers (e.g. BRCA1/2 mutation status for breast cancer, or faecal immunochemical test results for colorectal cancer) and imaging findings (e.g. mammography for breast cancer), could potentially enhance model discrimination.